The Bull Case For Onto Innovation (ONTO) Could Change Following Dragonfly G5 HBM4 Inspection Wins - Learn Why

• Earlier this month, Onto Innovation Inc. launched its Dragonfly G5 inspection and metrology system, securing double-digit orders from a high bandwidth memory manufacturer for HBM4 ramp, with shipments scheduled to begin in the second quarter of 2026.
• The Dragonfly G5’s finer defect sensitivity, higher throughput, and expanded machine learning capabilities highlight how Onto Innovation is deepening its role in advanced semiconductor packaging process control.
• Next, we’ll explore how the Dragonfly G5’s strong HBM4 order momentum could influence Onto Innovation’s existing investment narrative.

Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

Onto Innovation Investment Narrative Recap

To own Onto Innovation, you need to believe its process control tools stay central to AI and advanced packaging, and that customer demand rebounds as expected. The Dragonfly G5 HBM4 orders support the near term growth catalyst around AI packaging, but they do not remove key risks such as reliance on a few large customers and the need for sustained high R&D spending.

The most relevant recent announcement to this HBM4 win is the pending integration of Semilab product lines into Onto’s portfolio, which broadens its reach in electrical metrology and advanced packaging. Together with Dragonfly G5 and 3Di, this could reinforce Onto’s role across both front end and back end process steps and potentially help offset some of the revenue concentration risk tied to a handful of HBM and AI logic customers.

Yet this positive HBM4 momentum sits alongside an important risk investors should be aware of around customer concentration and what happens if one key account were to...

Read the full narrative on Onto Innovation (it's free!)

Onto Innovation’s narrative projects $1.4 billion revenue and $311.2 million earnings by 2028.

Uncover how Onto Innovation's forecasts yield a $265.71 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming about US$1.7 billion of revenue and US$457.0 million of earnings by 2029, yet they still flag higher costs and tighter market access as major risks, reminding you that equally informed people can see Onto’s HBM4 orders as either reinforcing the story or as something that may or may not shift a more cautious view over time.

Explore 5 other fair value estimates on Onto Innovation - why the stock might be worth as much as 30% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Onto Innovation research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Onto Innovation research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Onto Innovation's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com